Skip to main content
. Author manuscript; available in PMC: 2018 Jan 12.
Published in final edited form as: Clin Skin Cancer. 2016 Nov 23;1(1):26–29. doi: 10.1016/j.clsc.2016.11.001

Figure 2. Clinical Progress.

Figure 2

Cutaneous SCC regression changes observed on clinical follow-up from baseline at start of prembolizumab (a), 2 ½ months of treatment (b), and 10 months of treatment (c).